---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-001763"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T19:02:57.516103+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics Q1 2025 net loss $1.7M; cash $6.2M; SIL204 shows ~70-80% tumor reduction

## Summary
- Net loss $1.7M in Q1 2025 vs $1.4M in Q1 2024; total operating expenses $1.7M (R&D $0.6M, G&A $1.1M).
- Cash and cash equivalents $6.2M as of Mar 31, 2025, up from $1.2M in Dec 31, 2024, after ~$9.2M gross raised.
- SIL204 orthotopic data: ~70% tumor cell reduction in AsPC-1 (G12D) and ~80% in BxPC-3 by day 28; reduced metastases.
- Expanded dual-route (systemic + intratumoral) development strategy for SIL204; clinical trials targeted for H1 2026.
- Post-quarter strategic collaboration with Catalent for formulation and clinical manufacturing of SIL204.

## SEC filing metadata
- accession: 0001178913-25-001763
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/0001178913-25-001763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001763/zk2533189.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-001763
- JSON: https://secwatch.observer/filing/0001178913-25-001763.json
- Plain text: https://secwatch.observer/filing/0001178913-25-001763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.